Mesothelin as a target for cervical cancer therapy
- 99 Downloads
The cell surface glycoprotein Mesothelin is overexpressed in several tumor entities and novel immune-based therapies are currently under the early clinical evaluation for the treatment of malignant pleura mesothelioma, ovarian cancer, and pancreatic cancer. Cervical cancer has not been recognized as a suitable target for Mesothelin-directed immune therapies so far.
To exploit a possible role of Mesothelin in cervical cancer treatment, we analysed Mesothelin expression in 79 cervical carcinomas and aligned expressions patterns with tumor growth parameters. A novel anti-Mesothelin drug conjugate (Anetumab Ravtansine) was applied for dose-efficiency studies in a Mesothelin positive tumor model for cervical cancer in Scid mice.
In more than three-quarters (77%) of cervical adenocarcinomas, Mesothelin was expressed to high levels. Among squamous cell carcinomas of the cervix uteri expression levels were lower and expression patterns were less intense, but still ranged between 50–60% (57%). A significant correlation between Mesothelin expression levels and tumor grade, metastatic behaviour, and lymph- or hemangiosis was not found. The novel anti-Mesothelin-drug conjugate (Anetumab Ravtansine) showed a substantial dose-dependent therapeutic efficiency in a xenotransplant model for cervical cancer in SCID mice (hela cell tumors). Applying the ADC at a dose of 10 mg/kg twice weekly induced complete tumor regression in 88% of animals within 6 weeks.
Mesothelin should be taken into account as a target in cervical cancer therapy and histological determination of Mesothelin expression should be considered in routine diagnostics of cervical carcinomas.
KeywordsMesothelin Cervical cancer Cervical adenocarcinomas Anetumab ravtansine
This study was funded by the Bundesministerium für Bildung und Forschung (BMBF) 03V0347 and the Bayer AG. The authors would like to thank Natalie Kuzaj and Andrea Wilke for the excellent technical support.
KJ investigation and methodology; LL methodology; JB writing, review, and editing; JS supervision; GC conceptualization, writing, review, and editing.
Compliance with ethical standards
Conflict of interest
Dr. Cichon received grant monies from Bayer AG. Prof. Sehouli receives funding for studies in ovarian cancer and serves on the Advisory Board as a consultant for Bayer. The other authors have no conflict of interest to declare.
- 4.Reiter Y, Pastan I (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 2:245–252Google Scholar
- 5.Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149CrossRefGoogle Scholar
- 6.Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M et al (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311–3319CrossRefGoogle Scholar
- 7.Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20Google Scholar
- 15.Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M et al (2017) Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 8(28):46425–46435Google Scholar
- 18.Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020–1028CrossRefGoogle Scholar
- 23.Bendell J, Blumenschein G, Zinner R, et al. (2016) First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American 86 clinical cancer drugs 3; no. 2Google Scholar
- 24.Hassan et al. (2015) Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (ID 1574; oral presentation). In: 16th World Conference on Lung Cancer WCLC 2015 in Denver, Colorado, September 6–9, 20Google Scholar